PierianDx said it has acquired Tute Genomics for an undisclosed price, in a deal the buyer said advances its goal of enabling personalized medicine for clinical labs through a comprehensive, integrated platform.
PierianDx said it will enhance its Clinical Genomicist Workspace (CGW), a cloud-based software platform for somatic cancer, by adding Tute Genomics’ constitutional and exome-testing capabilities.
“The enhanced platform will provide labs with a single clinical solution to support a comprehensive range of molecular testing for personalized medicine,” PierianDx CEO Ted Briscoe said in a statement.
However, PierianDx added that it will maintain the Tute Genomics solution until the platforms are fully integrated into CGW 6.0 in the spring of 2017.
Tute CEO Reid Robison will join PierianDx’s board, and Tute COO Andy Olson and the acquired company’s vp of product development, Bryce Daines, will relocate to St. Louis, where PierianDx is based.
PierianDx added that it will maintain a development team in Provo, UT, where Tute Genomics has been based.
Founded in 2012, Tute Genomics was co-founded by Kai Wang, Ph.D., a renowned computational biologist and inventor of ANNOVAR software, and Reid Robison, M.D., M.B.A., a physician, geneticist, and entrepreneur.
In December 2015, Tute Genomics acquired the human-genome interpretation company Knome, co-founded by geneticist and Harvard professor George Church, Ph.D., for an undisclosed price.